Sign In
Buy RDHL
$1.00
-0.0100 (-0.99%)
At Close: Jun 03, 2026
RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation
07:00am, Tuesday, 18'th Mar 2025
RedHill plans to submit UK MAA 1 for Talicia for H. pylori infection, using MHRA's 2 new fast-track approval process, referencing FDA approval, with potential UK approval in Q4/25 Listed by ACG 3
The planned innovative Phase 2 study of RHB-2041 will be the first ever clinical study in Crohn's Disease (CD) patients who are all MAP-positive, and will correlate mucosal healing with MAP2 infecti
RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum
07:00am, Thursday, 27'th Feb 2025
Guy Goldberg, RedHill's Chief Business Officer, presents today a business update at the European Life Sciences CEO Forum The update covers: The recent out-licensing of RHB-102 [1] to Hyloris (Euronext
- Hyloris will pay RedHill an upfront payment and up to $60 million in potential milestone payments, plus up to mid-20s percent royalties on revenues, in return for exclusive rights to develop and com
RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer
07:00am, Tuesday, 04'th Feb 2025
The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant prostate cancer (m
Talicia is now covered by Humana's Part D Plan, providing access to Talicia for H. pylori therapy to more than eight million additional Medicare lives, without requiring prior therapeutic steps or aut
Heightened geopolitical tensions and Homeland Security concerns call for the development of potential therapies that can be quickly and easily mobilized in the event of a mass casualty nuclear or radi
RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court
07:00am, Monday, 02'nd Dec 2024
RedHill has been awarded a judgment of approximately $8 million plus costs in a summary judgment by the New York Supreme Court in its legal proceedings against Kukbo Co. Ltd The Court dismissed the en
RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND
07:00am, Monday, 28'th Oct 2024
RedHill has been selected to provide a presentation to further elaborate on opaganib's potential to U.S. government representatives at the Joint Program Executive Office for Chemical, Biological, Rad
The collaboration outlines plans for multiple in vivo studies, designed to test opaganib as a potential medical countermeasure to treat phosgene inhalation injury. The collaboration aims to determine
RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment
07:00am, Monday, 14'th Oct 2024
The U.S. government's Biomedical Advanced Research and Development Authority (BARDA) selected opaganib for joint development & funding as a medical countermeasure (MCM) to treat Ebola virus disease (E
RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians
07:00am, Tuesday, 01'st Oct 2024
Medi-Cal, California's Medicaid healthcare program, and RedHill have renewed their contract to maintain Talicia's first-line position on the Medi-Cal Fee-For-Service (FFS) Contract Drug List (CDL) wit
RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041
07:00am, Monday, 30'th Sep 2024
New U.S. patent issued covering the identification of a novel biomarker of coronavirus pneumonia (≤60% fraction of inspired oxygen (FiO2)) prognostic for potential opaganib efficacy in treating COVI
RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines
07:00am, Monday, 09'th Sep 2024
First new American College of Gastroenterology (ACG) Clinical Guideline [1] for H. pylori infection since Talicia's approval lists Talicia as an empirically prescribed first-line option Talicia's conv
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
07:00am, Thursday, 05'th Sep 2024
TEL AVIV, Israel and RALEIGH, N.C. , Sept. 5, 2024 /PRNewswire/ -- RedHill Biopharma Ltd.
